Kumaril Bhargava, Ph.D., MBA, R.Ph.


Kumaril Bhargava is the founder of Serentrix, LLC, a company developing compounds for pain.  Dr. Bhargava was part of the External Research & Development Innovation group at Merck and Pfizer where he played a key role in acquiring multiple technologies and companies and establishing collaborations with biotech firms and academia.  He also served as a Director of Strategic Marketing for Procrit™ at Johnson & Johnson. He has more than twenty years of experience in R&D, Supply Chain, Sales and marketing and Business development gained at Abbott, Wyeth/Pfizer, Johnson & Johnson and Merck.

Dr. Bhargava holds a Bachelor’s degree in Pharmacy from Birla Institute of Technology & Science, Pilani, India, a Ph.D. in Pharmaceutical Sciences, and an MBA from the University of Chicago.  He is a licensed pharmacist in the State of Pennsylvania and New Jersey.

Dr. Peter Sol Reinach, Ph.D.

Chief Scientific Officer

Dr. Peter sol Reinach’s has co authored 168 peer reviewed scientific articles, written 10 book chapters and written 6 review articles dealing with the polymodal roles of transient receptor potential channels in ocular health and disease. Currently, his research activity has been cited by others nearly 6,000 times.  Besides he is a scientific reviewer of numerous peer reviewed journals and the member of several editorial boards. His research activities were continuously funded for more than 30 years from the National Eye Institute along with pharmaceutical contract and university departmental support. He continues to be a FARVO member of the Association for Research in Ophthalmology and Vision and also of the International Society of Eye Research.

His educational and professional background includes graduating from New York University  with a PhD in biophysics during which time he received an excellence award for his thesis outcome as well as a NSF fellowship to attend an international biophysics meeting in the former Soviet Union. His continuous National Eye Institute funding gave him the opportunity to broaden his research interests to initiate studies on receptor mediated control of responses underlying control of ocular epithelial renewal. He continued in this line of work after relocating to the State University of New York and also being appointed Adjunct Professor of Ophthalmology at Columbia University. During this tenure, he was course director of pharmacology instruction besides teaching various courses dealing with ocular diseases.